Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/9306
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Branford, S. | - |
dc.contributor.author | Rudzki, Z. | - |
dc.contributor.author | Walsh, S. | - |
dc.contributor.author | Grigg, A. | - |
dc.contributor.author | Arthur, C. | - |
dc.contributor.author | Taylor, K. | - |
dc.contributor.author | Herrmann, R. | - |
dc.contributor.author | Lynch, K. | - |
dc.contributor.author | Hughes, T. | - |
dc.date.issued | 2002 | - |
dc.identifier.citation | Blood, 2002; 99(9):3472-3475 | - |
dc.identifier.issn | 0006-4971 | - |
dc.identifier.issn | 1528-0020 | - |
dc.identifier.uri | http://hdl.handle.net/2440/9306 | - |
dc.description | © 2002 by The American Society of Hematology. | - |
dc.description.abstract | Point mutations were found in the adenosine triphosphate (ATP) binding region of BCR/ABL in 12 of 18 patients with chronic myeloid leukemia (CML) or Ph-positive acute lymphoblastic leukemia (Ph+ ALL) and imatinib resistance (defined as loss of established hematologic response), but they were found in only 1 of 10 patients with CML with imatinib refractoriness (failure to achieve cytogenetic response). In 10 of 10 patients for whom samples were available, the mutation was not detected before the initiation of imatinib therapy. Three mutations (T315I, Y253H, and F317L present in 3, 1, and 1 patients, respectively) have a predicted role in abrogating imatinib binding to BCR/ABL, whereas 3 other mutations (E255K, G250E, and M351T, present in 4, 2, and 2 patients, respectively) do not. Thus we confirm a high frequency of mutations clustered within the ATP-binding region of BCR/ABL in resistant patients. Screening may allow intervention before relapse by identifying emerging mutations with defined impacts on imatinib binding. Certain mutations may respond to higher doses of imatinib, whereas other mutations may mandate switching to another therapeutic strategy. | - |
dc.language.iso | en | - |
dc.publisher | Amer Soc Hematology | - |
dc.source.uri | http://bloodjournal.hematologylibrary.org/cgi/content/abstract/99/9/3472 | - |
dc.subject | Humans | - |
dc.subject | Benzamides | - |
dc.subject | Piperazines | - |
dc.subject | Pyrimidines | - |
dc.subject | Fusion Proteins, bcr-abl | - |
dc.subject | Adenosine Triphosphate | - |
dc.subject | DNA Mutational Analysis | - |
dc.subject | Binding Sites | - |
dc.subject | Drug Resistance, Neoplasm | - |
dc.subject | Gene Frequency | - |
dc.subject | Point Mutation | - |
dc.subject | Adult | - |
dc.subject | Aged | - |
dc.subject | Middle Aged | - |
dc.subject | Female | - |
dc.subject | Male | - |
dc.subject | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | - |
dc.subject | Precursor Cell Lymphoblastic Leukemia-Lymphoma | - |
dc.subject | Imatinib Mesylate | - |
dc.title | High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance | - |
dc.type | Journal article | - |
dc.identifier.doi | 10.1182/blood.V99.9.3472 | - |
pubs.publication-status | Published | - |
dc.identifier.orcid | Branford, S. [0000-0002-1964-3626] [0000-0002-5095-7981] | - |
dc.identifier.orcid | Hughes, T. [0000-0002-0910-3730] [0000-0002-7990-4509] | - |
Appears in Collections: | Aurora harvest 4 Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.